CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended		197 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Cash flows from operating activities:
Net loss	$ (3,043,931)	$ (2,473,906)	$ (90,854,356)
Adjustments to reconcile net loss to net cash used by operating activities:
Common stock issued as inducement to convert convertible notes payable and accrued interest			3,351,961
Issuance of common stock to consultants for services	65,468		95,468
Depreciation and amortization	31,585	21,415	2,535,606
Amortization of debt discount	181,350	382,478	2,647,079
Gain on disposal of property and equipment			(21,663)
Gain on extinguishment of debt			(216,617)
Interest expense paid with Series B Preferred Stock in connection with conversion of notes payable			3,147
Abandoned patents			183,556
Bad debts - employee advances			255,882
Contributed technology expense			4,550,000
Consulting expense			237,836
Management unit expense			1,334,285
Expense for issuance of warrants			533,648
Expense for issuance of options	266,490	4,532	2,834,678
Amortization of deferred compensation			74,938
Penalties in connection with non-registration event			361,496
Changes in operating assets and liabilities:
Accounts receivable	(32,286)	(7,316)	(84,065)
Inventories	205,822	(104,236)	(476,550)
Prepaid expenses and other current assets	320,420	(102,340)	(427,221)
Other assets	9,442		(37,511)
Accounts payable and accrued expenses	162,428	60,581	3,268,232
Accrued interest expense			1,823,103
Net cash used by operating activities	(1,833,212)	(2,218,792)	(68,027,068)
Cash flows from investing activities:
Proceeds from sale of property and equipment			32,491
Purchases of property and equipment	(22,549)	(1,065)	(2,443,359)
Patent costs	(12,769)	(24,957)	(511,283)
Purchases of short-term investments			(393,607)
Proceeds from sale of short-term investments			393,607
Loan receivable			(1,632,168)
Net cash used by investing activities	(35,318)	(26,022)	(4,554,319)
Cash flows from financing activities:
Proceeds from issuance of common stock			400,490
Proceeds from issuance of preferred stock, net of related issuance costs			9,579,040
Equity contributions - net of fees incurred	899,967	2,100,000	50,971,278
Proceeds from borrowings	1,098,000	700,000	12,986,881
Proceeds from exercise of stock options	15,100		514,495
Proceeds from subscription receivables			15,746
Net cash provided by financing activities	2,013,067	2,800,000	74,467,930
Effect of exchange rates on cash	(3,269)		(15,931)
Net change in cash and cash equivalents	141,268	555,186	1,870,612
Cash and cash equivalents - beginning of period	1,729,344	1,186,653
Cash and cash equivalents - end of period	1,870,612	1,741,839	1,870,612
Supplemental disclosure of cash flow information:
Cash paid during the period for interest			590,189
Supplemental schedule of noncash investing and financing activities:
Debt discount in connection with issuance of convertible debt	188,468	87,700	1,832,973
Fair value of shares issued as costs of raising capital	20,632	213,584	604,118
Note payable principal and interest conversion to equity	1,226,042	395,153	13,175,491
Issuance of management units in settlement of cost of raising capital			437,206
Change in fair value of management units for cost of raising capital			278,087
Issuance of common stock in exchange for stock subscribed			399,395
Costs paid from proceeds in conjunction with issuance of preferred stock			768,063
Preferred stock dividends	1,202,905	1,241,121	12,124,940
Net effect of conversion of common stock to preferred stock prior to merger			559
Leasehold Improvements
Supplemental schedule of noncash investing and financing activities:
Issuance of member units			141,635
Loans Receivable
Supplemental schedule of noncash investing and financing activities:
Issuance of member units			1,632,168
Accounts Payable
Supplemental schedule of noncash investing and financing activities:
Issuance of member units			$ 1,614,446